Statement - Label changes for Tamiflu - Roche

Flu :: Statement - Label changes for Tamiflu - Roche

Tamiflu (oseltamivir phosphate) was demonstrated in clinical trials to be a safe and effective medication for influenza prevention and treatment. Tamiflu was approved in 1999 and has been used by more than 42 million people in over 80 countries.

Roche continuously reviews post-marketing safety information and provides regular updates to the regulatory agencies. Based upon reports received over the last influenza season Roche has agreed that the Tamiflu label in the US will be revised to include reports of neuropsychiatric events such as self-injury and delirium in patients with influenza. Reports of neuropsychiatric events in patients taking oseltamivir are very rare based on usage, and a causal relationship between the use of oseltamivir and the likelihood of neuropsychiatric events in influenza patients cannot be established.

In 2005, 103 psychological reports during treatment of influenza with Tamiflu were received, including 5 deaths. These events are extremely rare in relation to the number of patients treated during the influenza season. Based upon the information presented by the FDA we calculate that:

approximately 1 in 100'000 patients experienced psychological disorders
approximately 1 out of 2 million patients treated died

None of these events could be established to have been caused by Tamiflu.

Phase III pivotal trials conducted by Roche found similar reports of neurologic and psychiatric events in pediatric influenza patients being treated with Tamiflu and those receiving no treatment. In addition, a recent review of a US claims database showed no differences in the incidence of neuropsychiatric events between flu patients treated with Tamiflu and those who were not treated.

Influenza itself is a severe disease. High fever, which is a typical symptom of influenza, has been associated with neuropsychaitric disorders including hallucination or delirium.

The well-being of patients and the safe and effective use of our medications is a priority for Roche. Roche continues to monitor the safety of Tamiflu through established reporting mechanisms and notify regulatory authorities of adverse events in line with regulatory requirements.





(Flu :: Statement - Label changes for Tamiflu - Roche published at SpiritIndia on Saturday, November 18, 2006)

Flu

Search more information on Flu, Flu books

Recently posted related articles on Flu :

1. H1N1 flu :: Pandemic swine flu - H1N1 Influenza
2. Bird Flu :: Need for preparedness for potential flu pandemic
3. Flu :: No Vacation for Flu Virus
4. Bird Flu :: 12 year Indonesian boy dies of bird flu
5. Foot and Mouth Disease :: Smiths Detection to launch a portable diagnostic system for foot-and-mouth disease and avian flu
6. Bird Flu :: Grid computing offers new hope in race against bird flu
7. Bird Flu :: Mutated bird flu virus more infectious to humans
8. Bird Flu :: Researchers identify key step bird flu virus takes to spread readily in humans
9. Bird Flu :: Avian influenza – situation in Indonesia – update 17
10. Bird Flu :: Depopulation of birds complete at Saskatchewan farm, Canada

Most related articles:

- Flu :: Statement - Label changes for Tamiflu - Roche
- Tamiflu :: No evidence of Tamiflu resistance - Roche - 17.1
- Tamiflu linked to abnormal behavior - 12.4
- Bird Flu :: Roche's Tamiflu for influenza, to combat H5N1 bird flu virus - 12.3
- Influenza :: Roche update on Tamiflu for pandemic influenza preparedness - 11.8
- Influenza :: Roche files supplemental new drug application for Tamiflu - 10.1
- Tamiflu :: Roche's Tamiflu not linked to psychiatric symptoms - 10
- Influenza :: Tamiflu for Prevention of Influenza in Children - 9.8
- Influenza :: WHO data confirms low level of resistance to Tamiflu - 8.9
- Flu :: Flu drug Tamiflu may pose risk of mental side effects - FDA - 8.3

Flu - recent related articles/news stories:

- Eating late night snack causes weight gain, obesity
- Homeopathy Arsenic 30 preventive for H1N1 flu, says CCRH
- iPhone locates H1N1 swine flu and infectious diseases
- Swine flu cases decreasing in UK
- Homeopathy medicines and H1N1 - a rational approach needed

»»   Fungal Infections :: Novartis' Mycograb might be approved in Europe for serious fungal infections
««   Breast Implants :: Mentor MemoryGel Silicone Gel-Filled Breast Implants

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com